Glycolytic inhibitors, such as 3-bromopyruvate (3-BP) (Yun et al., 2009), MJE3 (Evans et al., 2005), 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) (Clem et al., 2008), 3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid (FX11) (Le et al., 2010), and dichloroacetate (DCA) (Sutendra and Michelakis, 2013) target HK2, PFKFB3, PGAM1, LDHA and PDH, respectively in cancer cells to effectively suppress tumor growth. Here, HK2 is linked to cancer.